



Date: May 26, 2023

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code: 543434**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: SUPRIYA**

Dear Sir (s),

**Sub: Audited financial results for the quarter and year ended on March 31, 2023 (Revised)**

This has reference to our letter dated May 26, 2023 regarding submission of Audited Financial Results for the Quarter and year ended March 31, 2023 pursuant to regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

In this connection, we would like to inform that the aforesaid audited results submitted to stock exchanges contain clerical error caused inadvertently.

Since only the Sr. No. (iii) of Liabilities (Non-Current Liabilities), Total Non-Current Liabilities and Total Equity & Liabilities of March 31, 2022 contains error which has rectified as mentioned in below table:

<b>Liabilities</b>	<b>March 31, 2022</b>
<b>Non-Current Liabilities</b>	
(iii) Deferred Tax Liabilities	111.49
Total Non-Current Liabilities	193.76
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>7347.62</b>

Kindly take the above said information on your records.

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)



**SUPRIYA LIFESCIENCE LTD.**  
*Creating true values that bind global health*

---

Thanking you,

Yours faithfully,

**For Supriya Lifescience Limited**

**Shweta Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A44973**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**

**SUPRIYA LIFESCENCE LIMITED**

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

Statement of Standalone Audited Financial Results for the Quarter &amp; Year Ended 31st March, 2023

(₹ In million)

Sr.No.	Particulars	Quarter ended 31-03-2023 Audited	Quarter ended 31-12-2022 Unaudited	Quarter ended 31-03-2022 Audited	Year ended 31-03-2023 Audited	Year ended 31-03-2022 Audited
	<b>Income</b>					
I	Revenue from Operations	1,422.70	1,051.40	1,812.69	4,609.38	5,300.49
II	Other Income	19.64	25.64	38.55	94.89	75.77
III	<b>Total Income</b>	<b>1,442.35</b>	<b>1,077.03</b>	<b>1,851.24</b>	<b>4,704.27</b>	<b>5,376.26</b>
2	<b>Expenses</b>					
	a) Cost of Materials Consumed	475.20	547.19	382.42	1,873.18	1,988.30
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	0.39	(33.71)	325.89	(65.06)	(30.26)
	d. Employee benefit expenses	153.01	146.45	128.69	555.78	490.78
	e. Finance Cost	7.14	10.14	10.17	30.84	41.98
	f. Depreciation & amortisation expense	30.07	29.50	25.79	118.15	101.18
	g. Other expenditure	243.65	251.03	223.46	956.49	711.82
IV	<b>Total Expenses</b>	<b>909.46</b>	<b>950.60</b>	<b>1,096.43</b>	<b>3,469.40</b>	<b>3,303.81</b>
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	532.89	126.43	754.81	1,234.87	2,072.45
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	532.89	126.43	754.81	1,234.87	2,072.45
VIII	<b>Tax Expense</b>					
	a) Current Tax	132.07	24.21	184.45	306.81	521.89
	b) Deferred Tax	18.53	7.05	108.25	29.49	32.46
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	382.29	95.18	462.11	898.57	1,518.10
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	382.29	95.18	462.11	898.57	1,518.10
XIV	<b>Other Comprehensive Income</b>					
	A (i) Items that will not be reclassified to profit or loss	(6.22)	(0.34)	1.55	(16.80)	(4.22)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	1.56	0.09	(0.37)	4.23	1.08
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>377.63</b>	<b>94.92</b>	<b>463.28</b>	<b>886.00</b>	<b>1,514.95</b>
XVI	<b>Earnings per equity Share (for continuing operation):</b>					
	(1) Basic (In ₹)	4.75	1.18	5.74	11.16	18.86
	(2) Diluted (In ₹)	4.75	1.18	5.74	11.16	18.86
XVII	<b>Earnings per equity Share (for discontinued operation):</b>					
	(1) Basic (In ₹)	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-
XVIII	<b>Earnings per equity Share (for discontinued &amp; continuing operations):</b>					
	(1) Basic (In ₹)	4.75	1.18	5.74	11.16	18.86
	(2) Diluted (In ₹)	4.75	1.18	5.74	11.16	18.86




See accompanying notes to the financial statements:

**Notes:-**

1. The Audited Standalone financial results of the Company for the quarter & year ended March 31, 2023 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above Audited standalone financial results of the Company for the quarter & year ended March 31, 2023 have been reviewed by the Audit Committee on 26th May, 2023 and thereafter approved by the Board of Directors at their meeting held on 26th May, 2023.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The Board of Directors at their meeting held on May 26, 2023 have recommended final dividend of Rs. 0.60/- per equity share of Rs. 2/- each.
5. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.
6. The standalone annual financial results include the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For and on behalf of The Board of directors of  
Supriya Lifescience Ltd.





Dr. Saloni Wagh  
Whole Time Director  
DIN: 08491410

PLACE :- MUMBAI  
DATE :- 26/05/2023



## Supriya Lifescience Ltd

CIN No: L51900MH2008PLC180452

Standalone Balance Sheet as at March 31, 2023

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	Notes	March 31, 2023	March 31, 2022
<b>ASSETS</b>			
<b>Non-current assets</b>			
(i) Property, plant and equipment	3	2,551.17	1,824.68
(ii) Right to Use Asset	3	53.15	57.97
(iii) Capital Work in progress	5	676.28	434.09
(iv) Intangible Assets	4	11.06	15.09
(v) Financial Assets		0	
-Investments	6	252.96	0.53
-Loans and Advances	7	-	-
(vi) Other Non- Current Assets	8	9.28	39.84
		0	
<b>Total Non-current assets</b>		<b>3,553.90</b>	<b>2,372.18</b>
<b>Current assets</b>			
(i) Inventories	9	1,157.70	923.12
(ii) Financial Assets		0	
-Loans and Advances	7	5.49	5.74
-Trade receivables	10	846.64	1,151.83
-Cash and cash equivalents	11(a)	852.51	1,657.76
-Bank balances other than (iii) above	11(a)	723.31	621.32
-Other Financial Assets	11(b)	64.06	60.32
(iii) Other current assets	12	999.16	555.34
<b>Total Current Assets</b>		<b>4,648.87</b>	<b>4,975.44</b>
<b>TOTAL ASSETS</b>		<b>8,202.77</b>	<b>7,347.62</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(i) Equity share capital	13	160.97	160.97
(ii) Other equity	14	6,833.62	5,995.91
<b>Total Equity</b>		<b>6,994.58</b>	<b>6,156.87</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
(i) Financial Liabilities			
-Borrowings	15	-	-
-Lease Liabilities	16	54.89	52.95
-Other financial liabilities	17	-	-
(ii) Provisions	18	58.75	29.31
(iii) Deferred tax Liabilities	20	136.75	111.49
<b>Total Non-Current Liabilities</b>		<b>250.39</b>	<b>193.76</b>
<b>Current liabilities</b>			
(i) Financial liabilities			
-Borrowings	15	166.25	212.95
-Lease Liabilities	16	3.54	8.25
-Trade payables	19	642.28	489.72
-Other financial liabilities	17	8.21	7.94
(ii) Provisions	18	8.37	4.12
(iii) Other current liabilities	21	129.16	274.01
<b>Total Current Liabilities</b>		<b>957.80</b>	<b>996.99</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>8,202.77</b>	<b>7,347.62</b>

For and on behalf of The Board of directors of  
Supriya Lifescience Ltd.Dr. Saloni Wagh  
Whole Time Director  
DIN: 08491410PLACE :- MUMBAI  
DATE :- 26/05/2023



Supriya Lifescience Ltd  
CIN No: L51900MH2008PLC180452  
Cash flow statement for the year ended March 31, 2023  
(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	For the year ended March 31,2023	For the year ended March 31,2022
<b>A CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	1234.87	2,072.45
<b>Adjustments for</b>		
Depreciation and Amortization	118.06	101.18
Interest Income	-94.94	(70.70)
Interest on Lease Liability		(3.36)
Finance Cost	30.84	41.59
Provision for Bad debts		
Loss on Sale of fixed Assets	1.11	
Non Cash Expenses	16.88	
<b>Operating profit before working capital changes</b>	<b>1,306.82</b>	<b>2,141.16</b>
<b>Adjustments for movement in working capital</b>		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	305.19	(416.83)
Inventories	(234.58)	(198.32)
Other Current Assets	(447.55)	(288.83)
Loans and Advances	0.26	(30.53)
Other Non Current Assets	30.55	(28.59)
	<b>(346.13)</b>	<b>(963.10)</b>
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	152.56	(20.50)
Short term / Long term provisions	-	7.14
Other Financial Liabilities	0.27	(194.86)
Other Current liabilities	(163.09)	127.79
	<b>(10.26)</b>	<b>(80.43)</b>
(Income tax paid)/net of refund	(288.56)	(609.62)
<b>Net Cash generated from Operating Activities</b>	<b>661.87</b>	<b>488.01</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	(1,084)	(599.04)
(Purchase)/ Sale of Investments	-252.43	
Sale of fixed Assets	5.43	0.82
<b>Net Cash generated/(outflow) from Investing Activities</b>	<b>(1,331.45)</b>	<b>(598.22)</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Issue of Shares	-	2,000.00
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	(46.70)	(486.07)
Finance Cost	(30.84)	(36.58)
Dividend Paid	(48.29)	(43.91)
Interest Income	94.94	70.70
Repayment of Lease liability	-2.78	(7.63)
<b>Net Cash generated from Financing Activities</b>	<b>(33.68)</b>	<b>1,496.52</b>
<b>Net Increase/(Decrease) in Cash and Cash equivalents</b>	<b>(703.26)</b>	<b>1,386.31</b>
Cash and Cash Equivalents at the end of previous period	2,279.08	892.77
<b>Cash and Cash Equivalents as at the end of the reporting period</b>	<b>1,575.82</b>	<b>2,279.08</b>

For and on behalf of The Board of directors of  
Supriya Lifescience Ltd.



Dr. Saloni Wagh  
Whole Time Director  
DIN: 08491410

PLACE :- MUMBAI  
DATE :- 26/05/2023

**KAKARIA AND ASSOCIATES LLP**

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF. :

OUR REF. :

**INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF  
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF SUPRIYA LIFESCIENCE  
LIMITED**

**Opinion**

We have audited the accompanying Statement of Standalone Financial Results of **SUPRIYA LIFESCIENCE LIMITED** ("the Company"), for the three months and year ended March 31, 2023 ("the Statement" / "Standalone Financial Results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").


In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financials statement:

- a. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West

Mumbai - 400 053 Tele : 022 26744670. Email: [mumbai.kakaria@gmail.com](mailto:mumbai.kakaria@gmail.com),

Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)



income and other financial information of the Company for the three months and year ended March 31, 2023.

### **Basis for Opinion**

We conducted our audit of these Standalone Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Management's Responsibilities for the Standalone Financial Results**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim Condensed Standalone Financial Statements for the three months and year ended March 31, 2023. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Ind AS 34 prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and





for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.





- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For,  
Kakaria and Associates LLP  
Chartered Accountants.  
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria  
Partner  
Membership No. - 035416  
Place: - Mumbai  
Date: - 26.05.2023  
UDIN: - 23035416BGTHXG5186